Healio

Protecting the corneal endothelial cells during cataract surgery

Please provide your email address to receive an email when new articles are posted on . Patients who have both Fuchs' endothelial dystrophy and cataracts pose a challenging situation. The cornea ...
Nasdaq

Design Therapeutics Announces Update on DT-168 Program for Fuchs Endothelial Corneal Dystrophy at Eyecelerator 2025

Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...

Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial ...

Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 ...
Medscape

Diabetes Link Found for Fuchs Corneal Endothelial Dystrophy

Diabetes, especially type 1 diabetes, may be a particularly important factor in the etiology of Fuchs endothelial corneal dystrophy (FECD) in findings from a case-control study of about 149.000 US ...
Mena FN

Fuchs Endothelial Corneal Dystrophy Market Analysis: Epidemiology Insights, Therapies, Companies, By Delveinsight Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon

"Fuchs endothelial corneal dystrophy (FECD) Market Analysis"The total Fuchs Endothelial Corneal Dystrophy (FECD) market size of in the 7MM in 2023 was approximately ~USD 858 million, this is ...
EurekAlert!

Corneal thickness linked to early stage Fuchs' Endothelial Corneal Dystrophy

A national consortium of researchers has published new findings that could change the standard of practice for those treating Fuchs' Endothelial Corneal Dystrophy (FECD), a disease characterized by ...
Business Wire

Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophies

SAN DIEGO--(BUSINESS WIRE)--Trefoil Therapeutics today announced it has initiated the first clinical trial of its engineered Fibroblast Growth Factor-1 TTHX1114 for the regenerative treatment of ...
Yahoo Finance

Fuchs Endothelial Corneal Dystrophy Market Report 2025-2035: Bausch + Lomb, Santen Pharmaceutical, and Trefoil Therapeutics, Actively Shaping the Competitive Landscape

Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "Fuchs Endothelial Corneal Dystrophy Market - A Global and Regional Analysis: Focus on Treatment Method, End User, and Region - Analysis and Forecast, ...
Mena FN

Fuchs Endothelial Corneal Dystrophy Pharma Leaders Position For Market Share Amid Intensifying Global Competition Delveinsight

"Fuchs Endothelial Corneal Dystrophy Market Insight, Epidemiology and Market Forecast - 2034"The FECD market is expected to experience significant growth in the coming years, propelled by the ...
PharmiWeb

Fuchs Endothelial Corneal Dystrophy Market Report 2025-2035: Epidemiology, Regulatory Landscape, Ongoing Clinical Trials, Market Dynamics, Patent Analysis - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Fuchs Endothelial Corneal Dystrophy Market - A Global and Regional Analysis: Focus on Treatment Method, End User, and Region - Analysis and Forecast, 2025-2035" report ...
Business Wire

Trefoil Therapeutics’ Lead Investigational Candidate TTHX1114 Improves Rate of Visual Recovery after Descemet Stripping Only (DSO) in Phase 2 STORM Data Presented at ASCRS ...

SAN DIEGO--(BUSINESS WIRE)--Trefoil Therapeutics, a clinical-stage biotechnology company focused on developing novel new therapeutic agents to treat corneal diseases, today announced that TTHX1114 was ...